TEVATeva Pharmaceutical Industries Limited
Is it safe?
Nothing alarming, nothing pristine: insiders quiet, comfortable debt (A), and typical volatility.
Insiders were net sellers (-$17.0M, 90 days to Oct 8, 2026), selling is often routine.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Moderate price swings, typical volatility. Worst drawdown -88% · now at/near its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can TEVA take a bad year?
Teva Pharmaceutical Industries Limited carries $845M of net debt at 0.33× EBITDA: a load its earnings can carry.
Net debt · as at Q2 2026 · under two and a half years of EBITDA, comfortable
- Net debt / EBITDA
- 0.33×
Net debt / EBITDA · −0.90× a year ago · the load is going up
- Debt / equity
- 0.58×
Debt / equity
- Annualised volatility
- 44%
Annualised volatility · roughly twice as jumpy as the market
Details›
- Total debtQ2 2026
- $4.50B
- Cash and short-term investments
- $3.65B
- Net debt
- $845M
- EBITDA, trailing twelve months
- $2.59B
- Operating profit, trailing twelve months
- $1.60B
- Debt / equity
- 0.58×
- Total debt / EBITDA
- 1.74×
- Annualised volatilitytwo years of daily moves
- 44%
- Worst drawdown on file
- −88%
- Below its 52-week high
- 0.00%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers, Specialty & Generic
Ranks #14 of 41 by RyuScore